EU regulator backs Moderna's updated COVID vaccine
July 25 (Reuters) - The European Union's drug regulator has recommended approval of Moderna's MRNA.O updated formulation of COVID-19 shot Spikevax, the vaccine maker said on Friday.
The updated shot targets the LP.8.1 variant, part of the JN.1 lineage, to prevent COVID-19 in individuals six months of age and older, Moderna said.
It expects to make the mRNA-based shot available for the 2025-26 vaccination season, pending a European Commission approval.
Any recommendation by the European Medicines Agency's human medicines committee has to be formally approved by the EC, which usually follows the regulator's decision.
Moderna had filed a marketing application for the review of its updated vaccine with the U.S. Food and Drug Administration in May.
Related Articles
Coca Cola (KO) Q4 Earnings Preview: Look for the Upside in the AI Initiatives, not in the Revenue and the EPS
Coca-Cola (KO) enters its fourth-quarter 2025 earnings call tomorrow with significant momentum. However, a fundamental shift is occurring.
Warsh’s Fed Era Signals a Death Knell for QE, Jolting the $30 Trillion Treasury Market
With Warsh’s nomination, his past proposals for governing the Federal Reserve are being brought to the forefront. A central issue is the formulation of a new "1951 Accord" to restructure the relationship between the Fed and the Treasury. Analysts suggest such a move could impact the $30 trillion Tre
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.
